$2.52
(Market cap
$3,667 Mln
Recently Viewed
Clear AllMarket cap
$3,667 Mln
Revenue (TTM)
$392 Mln
P/E Ratio
--
P/B Ratio
8
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
Industry P/E
24.57
EV/EBITDA
-35.3
Debt to Equity
0
Book Value
$--
EPS
$-1.3
Face value
--
Shares outstanding
61,311,704
CFO
$-765.35 Mln
EBITDA
$-972.96 Mln
Net Profit
$-996.81 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Twist Bioscience Corp (TWST)
| 93.5 | 37.9 | 42.9 | 63.1 | 64.6 | -14.3 | -- |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Twist Bioscience Corp (TWST)
| -31.7 | 25.8 | 54.8 | -69.2 | -45.2 | 572.8 | -9.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Twist Bioscience Corp (TWST)
|
61.4 | 3,667.1 | 391.6 | -76.6 | -19.3 | -16.4 | -- | 8.0 |
| 12.4 | 3,993.9 | 3,018.8 | 72.1 | 12.6 | -80 | 56.9 | 105.4 | |
| 40.9 | 5,228.7 | 1,003.8 | 22.4 | 6.8 | 7.5 | 227.2 | 14.1 | |
| 187.9 | 9,667.5 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 109.5 | |
| 73.8 | 14,879.0 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 46.1 | 4,910.2 | 761.4 | 99.7 | 7.3 | 15 | 56.3 | 7.6 | |
| 13.6 | 11,337.9 | 3,45,831.0 | 56,586.0 | 21.5 | 15.8 | 18.6 | 2.8 | |
| 22.4 | 11,181.1 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.7 | |
| 8.1 | 7,186.6 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.5 | 1.0 | |
| 226.6 | 4,622.8 | 268.1 | 124.5 | 60.0 | 13.5 | 37.8 | 4.4 |
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage,... and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California. Read more
Co-Founder, Chairman & CEO
Dr. Emily Marine Leproust Ph.D.
Co-Founder, Chairman & CEO
Dr. Emily Marine Leproust Ph.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Twist Bioscience Corp (TWST) is $61.37 (NASDAQ) as of 24-Apr-2026 13:40 EDT. Twist Bioscience Corp (TWST) has given a return of 64.65% in the last 3 years.
Since, TTM earnings of Twist Bioscience Corp (TWST) is negative, P/E ratio is not available.
The P/B ratio of Twist Bioscience Corp (TWST) is 8.04 times as on 17-Apr-2026, a 41 premium to its peers’ median range of 5.70 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-21.74
|
3.57
|
|
2024
|
-12.55
|
5.54
|
|
2023
|
-5.64
|
1.85
|
|
2022
|
-8.73
|
2.41
|
|
2021
|
-33.76
|
8.84
|
The 52-week high and low of Twist Bioscience Corp (TWST) are Rs 66.00 and Rs 23.30 as of 25-Apr-2026.
Twist Bioscience Corp (TWST) has a market capitalisation of $ 3,667 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Twist Bioscience Corp (TWST), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.